SCHEMBL6571363

SCHEMBL6571363

COc1ccc(C(=O)NN=Cc2ccc(O)c(O)c2O)cc1

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.74
MIF P14174 1/20 0.61
HDAC3 O15379 1/20 0.61
HDAC4 P56524 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61
HDAC2 Q92769 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
HDAC9 Q9UKV0 1/20 0.61
HDAC5 Q9UQL6 1/20 0.61
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
KDM4E B2RXH2 2/20 0.58
NPC1 O15118 2/20 0.57
NTRK1 P04629 1/20 0.56
ALDH1A1 P00352 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28423171 1.00 MAPT (0.74) MAPTMIFHDAC3HDAC4HDAC1
SCHEMBL6571360 1.00 MAPT (0.74) MAPTMIFHDAC3HDAC4HDAC1
SCHEMBL28426747 0.85 MAPT (0.60) MAPTKMT2AMEN1KDM4ENPC1
SCHEMBL19283298 0.85 MAPT (0.79) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL19283300 0.85 MAPT (0.79) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL24185041 0.84 GCGR (0.75) MAPTKMT2AMEN1KDM4ENPC1
SCHEMBL32675182 0.84 GCGR (0.75) MAPTKMT2AMEN1KDM4ENPC1
SCHEMBL12388026 0.84 MAPT (0.71) MAPTKMT2AKDM4ENPC1
SCHEMBL28429011 0.83 MAPT (0.77) MAPTHDAC3HDAC4HDAC1HDAC7
SCHEMBL6752796 0.82 MAPT (0.75) MAPTHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO MAPT 3140/4885MIF 772/4885HDAC3 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.